Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.

STI 571 (formerly known as CGP 57148B) is a known inhibitor of the c-abl, bcr-abl, and platelet-derived growth-factor receptor (PDGFR) tyrosine kinases. This compound is being evaluated in clinical trials for the treatment of chronic myelogenous leukemia. We sought to extend the activity profile of STI 571 by testing its ability to inhibit the tyrosine kinase activity of c-kit, a receptor structurally similar to PDGFR. We treated a c-kit expressing a human myeloid leukemia cell line, M-07e, with STI 571 before stimulation with Steel factor (SLF). STI 571 inhibited c-kit autophosphorylation, activation of mitogen-activated protein (MAP) kinase, and activation of Akt without altering total protein levels of c-kit, MAP kinase, or Akt. The concentration that produced 50% inhibition for these effects was approximately 100 nmol/L. STI 571 also significantly decreased SLF-dependent growth of M-07e cells in a dose-dependent manner and blocked the antiapoptotic activity of SLF. In contrast, the compound had no effect on MAP kinase activation or cellular proliferation in response to granulocyte-macrophage colony-stimulating factor. We also tested the activity of STI 571 in a human mast cell leukemia cell line (HMC-1), which has an activated mutant form of c-kit. STI 571 had a more potent inhibitory effect on the kinase activity of this mutant receptor than it did on ligand-dependent activation of the wild-type receptor. These findings show that STI 571 selectively inhibits c-kit tyrosine kinase activity and downstream activation of target proteins involved in cellular proliferation and survival. This compound may be useful in treating cancers associated with increased c-kit kinase activity.

[1]  E. Russell.  Hereditary anemias of the mouse: a review for geneticists. , 1979, Advances in genetics.

[2]  In vivo differentiation of mast cells. , 1985, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society.

[3]  John E. Murphy,et al.  A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.

[4]  A. Ullrich,et al.  Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.

[5]  G. Dewald,et al.  Establishment of an immature mast cell line from a patient with mast cell leukemia. , 1988, Leukemia research.

[6]  A. Nienhuis,et al.  COOH-terminal-modified interleukin-3 is retained intracellularly and stimulates autocrine growth. , 1989, Science.

[7]  A. Bernstein,et al.  Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice. , 1989, Genes & development.

[8]  P. Roche,et al.  Purification of Tryptase From a Human Mast Cell Line , 1990, Journal of leukocyte biology.

[9]  M. Brizzi,et al.  M‐07e human leukemic factor‐dependent cell line provides a rapid and sensitive bioassay for the human cytokines GM‐CSF and IL‐3 , 1990, Journal of cellular physiology.

[10]  P. Quesenberry,et al.  Effects of rrSCF on multiple cytokine responsive HPP-CFC generated from SCA+Lin- murine hematopoietic progenitors. , 1991, Experimental hematology.

[11]  S. Lev,et al.  A specific combination of substrates is involved in signal transduction by the kit‐encoded receptor. , 1991, The EMBO journal.

[12]  H. Kitayama,et al.  Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product , 1991 .

[13]  L. Ashman,et al.  Comparative analysis of signaling pathways between mast cell growth factor (c-kit ligand) and granulocyte-macrophage colony-stimulating factor in a human factor-dependent myeloid cell line involves phosphorylation of Raf-1, GTPase-activating protein and mitogen-activated protein kinase. , 1991, Experimental hematology.

[14]  R. Ueda,et al.  Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. , 1991, Cancer research.

[15]  C. Brannan,et al.  Requirement for mast cell growth factor for primordial germ cell survival in culture , 1991, Nature.

[16]  T Takahashi,et al.  Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. , 1991, Oncogene.

[17]  J. Adamson,et al.  Stem cell factor induces proliferation and differentiation of highly enriched murine hematopoietic cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Kitayama,et al.  Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product. , 1991, Blood.

[19]  C. Langefeld,et al.  Mast cell growth factor (c-kit ligand) enhances cytokine stimulation of proliferation of the human factor-dependent cell line, M07e. , 1991, Experimental hematology.

[20]  M. Tsai,et al.  Induction of mast cell proliferation, maturation, and heparin synthesis by the rat c-kit ligand, stem cell factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Hallek,et al.  Granulocyte-macrophage colony-stimulating factor, interleukin-3, and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase. , 1992, Blood.

[22]  A. Ullrich,et al.  Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. , 1992, Cancer research.

[23]  B. Leclair,et al.  Expression of stem cell factor and c-kit mRNA in cultured endothelial cells, monocytes and cloned human bone marrow stromal cells (CFU-RF). , 1992, Experimental hematology.

[24]  K. Zsebo,et al.  Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors. , 1992, Blood.

[25]  M. Heinrich,et al.  Specific repression of granulocyte-macrophage and granulocyte colony-stimulating factor gene expression in interleukin-1-stimulated endothelial cells with antisense oligodeoxynucleotides. , 1992, Blood.

[26]  T. Tsukamoto,et al.  Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. , 1993, Cancer research.

[27]  M. Heinrich,et al.  Constitutive expression of steel factor gene by human stromal cells , 1993 .

[28]  R. Seeger,et al.  Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group , 1994 .

[29]  M. Ratajczak,et al.  STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  C. Heldin,et al.  Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. , 1994, Cancer research.

[31]  R. Seeger,et al.  Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group. , 1994, Blood.

[32]  H. Serve,et al.  Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. , 1994, The Journal of biological chemistry.

[33]  F. Galibert,et al.  Genomic structure of the downstream part of the human FLT3 gene: exon/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III. , 1994, Gene.

[34]  Andrius Kazlauskas,et al.  The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase , 1995, Cell.

[35]  N. Gross,et al.  Expression of stem cell factor and its receptor by human neuroblastoma cells and tumors. , 1995, Blood.

[36]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[37]  A. Gewirtz,et al.  Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. , 1995, The Journal of clinical investigation.

[38]  振津 琢磨.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product , 1995 .

[39]  N. S. Yee,et al.  Differential roles of PI3‐kinase and Kit tyrosine 821 in Kit receptor‐mediated proliferation, survival and cell adhesion in mast cells. , 1995, The EMBO journal.

[40]  John Malysz,et al.  W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity , 1995, Nature.

[41]  A. Hakura,et al.  An in vivo model for receptor tyrosine kinase autocrine/paracrine activation: auto-stimulated KIT receptor acts as a tumor promoting factor in papillomavirus-induced tumorigenesis. , 1995, Oncogene.

[42]  A. Burns,et al.  Impaired development of interstitial cells and intestinal electrical rhythmicity in steel mutants. , 1995, The American journal of physiology.

[43]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[44]  T Pawson,et al.  Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  G. Krystal,et al.  Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. , 1996, Cancer research.

[46]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[47]  S. Jacobsen,et al.  Ability of early acting cytokines to directly promote survival and suppress apoptosis of human primitive CD34+CD38- bone marrow cells with multilineage potential at the single-cell level: key role of thrombopoietin. , 1997, Blood.

[48]  S. Hirota,et al.  Ultrastructural identification of the c-kit-expressing interstitial cells in the rat stomach: a comparison of control and Ws/Ws mutant rats , 1997, Cell and Tissue Research.

[49]  M. Carroll,et al.  CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. , 1997, Blood.

[50]  G. Basso,et al.  Stem cell factor suppresses apoptosis in neuroblastoma cell lines. , 1997, Experimental hematology.

[51]  V. Broudy,et al.  Stem cell factor and hematopoiesis. , 1997, Blood.

[52]  R. DiPaola,et al.  Evidence for a functional kit receptor in melanoma, breast, and lung carcinoma cells. , 1997, Cancer gene therapy.

[53]  J. Litz,et al.  Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins. , 1997, Cancer research.

[54]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[55]  N. Sepp,et al.  Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. , 1998, The Journal of investigative dermatology.

[56]  Butterfield Jh.  Response of severe systemic mastocytosis to interferon alpha. , 1998 .

[57]  Butterfield.  Response of severe systemic mastocytosis to interferon alpha , 1998, The British journal of dermatology.

[58]  T. Hunter,et al.  The Kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136 , 1998, Current Biology.

[59]  S. Lyman,et al.  c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. , 1998, Blood.

[60]  T. Komuro,et al.  Ultrastructural characterization of interstitial cells of Cajal in the rat small intestine using control and Ws/Ws mutant rats , 1998, Cell and Tissue Research.

[61]  S. Hirota,et al.  A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. , 1998, Gastroenterology.

[62]  M. Heinrich,et al.  The Fanconi anemia group C gene product is located in both the nucleus and cytoplasm of human cells. , 1998, Blood.

[63]  S. Hirota,et al.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.

[64]  Z. Estrov,et al.  Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  D. Metcalfe,et al.  Clinical correlates of the presence of the asp816Val c‐kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis , 1998, Cancer.

[66]  R. Y. Chow,et al.  A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain. , 1999, The Biochemical journal.

[67]  D. Heitjan,et al.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[68]  P. Colombat,et al.  A rapid single‐laser flow cytometric method for discrimination of early apoptotic cells in a heterogenous cell population , 1999, British journal of haematology.

[69]  Y. Ma,et al.  Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms. , 1999, The Journal of investigative dermatology.

[70]  Li Sheng Wang,et al.  Retroviral-mediated gene transduction of c-kit into single hematopoietic progenitor cells from cord blood enhances erythroid colony formation and decreases sensitivity to inhibition by tumor necrosis factor-alpha and transforming growth factor-beta1. , 1999, Blood.

[71]  S. Hirota,et al.  Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. , 1999, Cancer research.

[72]  C. Marshall,et al.  Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors , 1999, Oncogene.

[73]  C. Moskaluk,et al.  Activating c-kit gene mutations in human germ cell tumors. , 1999, The American journal of pathology.

[74]  J. Lasota,et al.  Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. , 1999, The American journal of pathology.

[75]  G.,et al.  Annexin V for Flow Cytometric Detection of Phosphatidylserine Expression on B Cells Undergoing Apoptosis , 2000 .